Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).

Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).

Abstract: Methods of improving immune function in a cancer patient having a solid tumor are disclosed. The improvement in immune function may slow or stop tumor growth, and may reduce tumor load. Methods include administering effective amounts of a cancer treatment and a nonsteroidal glucocorticoid receptor modulator (GRM) or selective GRM (SGRM). The cancer treatment may include administration of a checkpoint inhibitor. GRM or SGRM administration may induce checkpoint-inhibitor sensitivity in the cancer. Improved immune function may include increased CD8+ T-cell activation, increased pro-inflammatory cytokine secretion, increased TNF? secretion, increased IFNy secretion, and other changes as compared to such activation and secretion prior to GRM administration. In embodiments, immune function is improved after 1, 2, 3, or more days of GRM administration. Other patient characteristics may also be improved by the methods disclosed herein.

Abstract: The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.

Abstract: Methods and compositions for treating a subject suffering from adrenocortical carcinoma and having excess cortisol are disclosed. The methods provide therapeutic benefits including reduction of ACC tumor load, restoration of T-cell and natural killer (NK) cell signaling pathways, increase in T-cell and NK cell infiltration into the ACC tumor, reduction of neutrophil infiltration into the ACC tumor in the patient, and other therapeutic benefits. The methods include administration of a glucocorticoid receptor modulator (GRM) (which may be a selective glucocorticoid receptor modulator (SGRM)) and an antibody checkpoint inhibitor. In embodiments, the GRM (e.g., a SGRM) is orally administered. The GRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).

Abstract: A linkage apparatus between a wheel suspension, mounted on the chassis of a motor vehicle accommodating the deflection or rebound of a motor vehicle wheel, and a rotation angle sensor connected to a control unit, having a connection rod with first and second ends, a first shaft capable of swiveling mounted on an end of the connection rod and connectable to the wheel suspension, a second shaft capable of swiveling mounted on an end of the connection rod and connectable to the rotation angle sensor, and at least one rotationally symmetrical body of elastically deformable material supporting at least one of the shafts, wherein the connecting rod is bent on at least one of its ends toward an essentially circular grommet that has been forced onto the at least one rotationally symmetrical body of elastically deformable material supporting at least one of the shafts.